Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HARVEST trial of high-dose oral rifampicin for tuberculous meningitis
ISRCTN15668391Phase 3Completed
- Sponsor
- Makerere University College of Health Sciences
- Start
- Jan 2020
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of rifampicin in meningeal tuberculosis (2 arms), sponsored by Makerere University College of Health Sciences. Primary endpoint: 6-month survival. Started Jan 2020; status: completed.
02
Drugs
rifampicin
03
Conditions
meningeal tuberculosis
Beyond the preview
Go deeper on ISRCTN15668391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15668391.